Literature DB >> 11703558

Melatonin protects against cardiac toxicity of doxorubicin in rat.

M F Xu1, S Ho, Z M Qian, P L Tang.   

Abstract

Doxorubicin (DOX) is commonly used for the treatment of hematological and solid tumors. However, there are serious toxic effects on the cardiovascular system, which limits the application of the drug. Recently, melatonin has been reported to have immunomodulatory effect in addition to lowering cholesterol levels as well as inhibiting malignant tumors. In this study, the effect of melatonin against the toxicity of doxorubicin was investigated in rats. Hemodynamic function, pathological and biochemical changes were determined in different treated hearts. Our findings showed that a significant protection by melatonin (6 mg kg(-1) for 15 days, cumulative dose of 90 mg kg(-1)) against the DOX-induced toxicity was observed. Cardiac function was improved and lipid peroxidation decreased after melatonin treatment. It is concluded that melatonin provides protection against doxorubicin toxicity via an attenuation of lipid peroxidation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703558     DOI: 10.1034/j.1600-079x.2001.310403.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  6 in total

1.  Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment.

Authors:  Yilmaz Cigremis; Hakan Parlakpinar; Alaadin Polat; Cemil Colak; Feral Ozturk; Engin Sahna; Necip Ermis; Ahmet Acet
Journal:  Mol Cell Biochem       Date:  2006-04-13       Impact factor: 3.396

Review 2.  Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.

Authors:  Martin Stěrba; Olga Popelová; Anna Vávrová; Eduard Jirkovský; Petra Kovaříková; Vladimír Geršl; Tomáš Simůnek
Journal:  Antioxid Redox Signal       Date:  2012-10-12       Impact factor: 8.401

Review 3.  Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing.

Authors:  Zhiqiang Ma; Liqun Xu; Dong Liu; Xiaoyan Zhang; Shouyin Di; Weimiao Li; Jiao Zhang; Russel J Reiter; Jing Han; Xiaofei Li; Xiaolong Yan
Journal:  Oxid Med Cell Longev       Date:  2020-05-21       Impact factor: 6.543

Review 4.  Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments.

Authors:  Anais Audebrand; Laurent Désaubry; Canan G Nebigil
Journal:  Front Cardiovasc Med       Date:  2020-01-24

Review 5.  Nanotechnology-based advances in the efficient delivery of melatonin.

Authors:  Mohammad Mirza-Aghazadeh-Attari; Ainaz Mihanfar; Bahman Yousefi; Maryam Majidinia
Journal:  Cancer Cell Int       Date:  2022-01-29       Impact factor: 5.722

Review 6.  Evidence for the Benefits of Melatonin in Cardiovascular Disease.

Authors:  Mohammad Tobeiha; Ameneh Jafari; Sara Fadaei; Seyed Mohammad Ali Mirazimi; Fatemeh Dashti; Atefeh Amiri; Haroon Khan; Zatollah Asemi; Russel J Reiter; Michael R Hamblin; Hamed Mirzaei
Journal:  Front Cardiovasc Med       Date:  2022-06-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.